Lipocut 120 Capsule contains Orlistat 120 mg, a potent gastrointestinal lipase inhibitor indicated for the management of obesity. Orlistat acts locally in the gastrointestinal tract by inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By preventing the breakdown and subsequent absorption of approximately 30% of dietary fat, Lipocut 120 facilitates weight reduction when used in conjunction with a reduced-calorie, low-fat diet. This medication is recommended for adult patients with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or greater who have obesity-related risk factors such as hypertension, type 2 diabetes, or dyslipidemia. Clinical studies have demonstrated that Lipocut 120, combined with lifestyle modifications, significantly improves weight loss outcomes and contributes to improvements in cardiovascular risk factors. Common adverse effects are primarily gastrointestinal and include oily spotting, flatulence with discharge, fecal urgency, and increased defecation, which are generally mild and related to dietary fat intake. Lipocut 120 should be used under medical supervision, with attention to fat-soluble vitamin supplementation and contraindications such as chronic malabsorption syndromes or cholestasis.